Shockwave Medical Inc. (SWAV)
(Delayed Data from NSDQ)
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Alcon's (ALC) Latest Buyout to Enhance Its Product Portfolio
by Zacks Equity Research
Alcon's (ALC) ophthalmic pharmaceutical product suite is expected to be significantly boosted by adding new products following the recent acquisition.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.
3 Medical Instruments Stocks to Buy as Inflation Clouds Prospects
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on rising demand for digital health. SWAV, MLAB and DYNT are set to gain the most. Yet, the ongoing inflation in the form of rising freight, raw material and labor costs is an overhang.
3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on the back of a series of product launches.
Alcon (ALC) Q3 Earnings Surpass Estimates, Sales Guidance Cut
by Zacks Equity Research
Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the strength in its comprehensive portfolio of PCIOLs, including PanOptix and Vivity.
PerkinElmer's (PKI) New Viral Vector Assays to Boost Workflows
by Zacks Equity Research
PerkinElmer's (PKI) latest launch is expected to help researchers expand options to measure viral titers, unlike ELISA and other wash-based systems.
Encompass Health (EHC) Proposes 50-Bed Hospital in Florida
by Zacks Equity Research
Encompass Health (EHC) intends to build a 50-bed inpatient rehabilitation hospital in the Daytona Beach area to further amplify its presence in Florida.
Here's Why You Should Bet on ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Medtronic (MDT) Q2 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Medtronic's (MDT) Q2 organic revenues reflect slower supply recovery and lower-than-anticipated underlying market procedure volumes in certain businesses.
Here's Why You Should Hold on to Abiomed (ABMD) Stock Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Merit Medical's (MMSI) New Launch to Boost Patient Outcome
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its radial portfolio is expected to significantly optimize hemostasis for radial artery procedures.
SmileDirectClub (SDC) Q3 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Challenges to consumer spending and sustained high inflation continue to impact SmileDirectClub's (SDC) overall expected demand for 2022.
Henry Schein's (HSIC) New Deal to Improve Patient Outcome
by Zacks Equity Research
Henry Schein's (HSIC) recent deal with Rimidi is expected to aid healthcare professionals in enhancing chronic disease management.
What's in the Cards for Medtronic (MDT) in Q2 Earnings?
by Zacks Equity Research
Medtronic's (MDT) Evolut PRO+ launch in Europe and Evolut PRO launch in China are expected to have contributed to the company's fiscal Q3 top line.
Neogen's (NEOG) Synergize Disinfectant Now Widely Available
by Zacks Equity Research
Availability of Neogen's (NEOG) Synergize Disinfectant in other markets is expected to enhance global biosecurity portfolios, thereby safeguarding the food chain from harmful diseases.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
NuVasive (NUVA) Q3 Earnings Beat Estimates, Guidance Cut
by Zacks Equity Research
The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.
Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Cardinal Health's (CAH) Velocare to Enhance at-Home Care
by Zacks Equity Research
Cardinal Health's (CAH) latest launch is expected to significantly expand its at-Home Solutions supply chain and logistics services, thereby improving patient care.
3 Reasons to Retain Abbott (ABT) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business.
PerkinElmer's (PKI) New Marketing Approval to Aid Infant Health
by Zacks Equity Research
PerkinElmer's (PKI) EONIS SCID-SMA assay kit is expected to enable early SMA and SCID screening in newborns following the FDA's approval.
Phibro (PAHC) Q1 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Phibro's (PAHC) growing uptake of MFAs, dairy products and vaccines buoys optimism.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
Patterson Companies' (PDCO) New Buyout to Expand Product Suite
by Zacks Equity Research
Patterson Companies' (PDCO) latest buyout is expected to significantly expand its Animal Health's product offerings.
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) third-quarter results benefit from the Technologies & Equipment business.